Phase II Bevacizumab With or Without AMG 386 in Recurrent Glioblastoma or Gliosarcoma
Glioblastoma · Gliosarcoma
Enrolment: 137 · Results not recorded
Loading the evidence…
Biologic
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Glioblastoma · Gliosarcoma
Enrolment: 137 · Results not recorded
Advanced Renal Cell Carcinoma
Enrolment: 41 · Results not recorded
Recurrent Uterine Corpus Carcinoma
Enrolment: 35 · Results not recorded
Adult Angiosarcoma · Soft Tissue Sarcoma
Enrolment: 16 · Results not recorded
Central Nervous System Neoplasm · Solid Neoplasm
Enrolment: 37 · Results not recorded
Adult Solid Neoplasm · Renal Cell Carcinoma · Carcinoid Tumor
Enrolment: 21 · Results not recorded
Ovarian Cancer
Enrolment: 150 · Results not recorded
ARDS, Human · COVID-19 ARDS
Enrolment: 39 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Contusion spinal cord injury
A single dose reduced vascular permeability at 48 hours but only transiently. Multiple administrations significantly decreased gastrointestinal vascular permeability at 4 weeks, improved sustained agonist-induced intestinal contraction and reduced ileal sICAM-1 compared with saline.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
Model: Cortical cold injury with blood-brain barrier breakdown and vasogenic oedema
Untreated cold-injured rats showed focal horseradish peroxidase leakage, increased endothelial caveolin-1 and decreased occludin in arterioles and venules with barrier breakdown, alongside increased Akt and ERK2. Angiopoietin-1 significantly reduced tracer leakage (P<0.001) and returned caveolin-1,…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.